"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines all ...
Diagnosis requires a tissue biopsy for histopathologic and immunohistochemistry evaluation. Testing for alterations using non-small cell lung cancer (NSCLC) tumor tissue requires acquisition of a ...
The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
In July 2025, the FDA greenlit the use of sunvozertinib (Zegfrovy) for pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...
Treatment modalities and survival outcomes in patients with hepatocellular carcinoma with brain metastases (HCC-BM): A large national study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer. The targeted therapy osimertinib (Tagrisso, AstraZeneca) improved progression-free survival (PFS) by ...
In 2006, Diana Lindsay, who had never so much as held a cigarette, was diagnosed with stage 4 lung cancer. It had metastasized to both lungs, her brain and lymph nodes. Keith Eaton, MD, PhD, clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results